Insider Selling: Sionna Therapeutics (NASDAQ:SION) Director Sells $5,270,902.00 in Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Peter Thompson sold 115,844 shares of the business’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $45.50, for a total transaction of $5,270,902.00. Following the sale, the director directly owned 2,555,877 shares of the company’s stock, valued at $116,292,403.50. This represents a 4.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sionna Therapeutics Stock Performance

Shares of SION opened at $43.99 on Friday. The firm has a market capitalization of $1.99 billion, a P/E ratio of -22.79 and a beta of 1.33. The stock’s fifty day simple moving average is $39.85 and its 200 day simple moving average is $39.53. Sionna Therapeutics, Inc. has a twelve month low of $16.38 and a twelve month high of $48.44.

Sionna Therapeutics (NASDAQ:SION) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.08). Sell-side analysts predict that Sionna Therapeutics, Inc. will post -2.57 earnings per share for the current year.

Institutional Investors Weigh In On Sionna Therapeutics

A number of large investors have recently modified their holdings of the stock. Deutsche Bank AG lifted its position in Sionna Therapeutics by 4.5% during the 4th quarter. Deutsche Bank AG now owns 10,029 shares of the company’s stock worth $413,000 after acquiring an additional 433 shares in the last quarter. Bank of America Corp DE grew its position in Sionna Therapeutics by 8.8% in the third quarter. Bank of America Corp DE now owns 6,541 shares of the company’s stock valued at $192,000 after acquiring an additional 529 shares in the last quarter. MetLife Investment Management LLC raised its stake in shares of Sionna Therapeutics by 6.6% during the fourth quarter. MetLife Investment Management LLC now owns 8,565 shares of the company’s stock valued at $352,000 after purchasing an additional 532 shares during the period. BNP Paribas Financial Markets raised its stake in shares of Sionna Therapeutics by 35.2% during the third quarter. BNP Paribas Financial Markets now owns 2,380 shares of the company’s stock valued at $70,000 after purchasing an additional 619 shares during the period. Finally, GF Fund Management CO. LTD. acquired a new position in shares of Sionna Therapeutics during the fourth quarter worth $36,000.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on SION shares. Freedom Capital downgraded shares of Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, May 20th. Wedbush assumed coverage on shares of Sionna Therapeutics in a research report on Tuesday, May 5th. They set an “outperform” rating and a $53.00 price target on the stock. Stifel Nicolaus boosted their price objective on shares of Sionna Therapeutics from $44.00 to $55.00 and gave the stock a “buy” rating in a research note on Monday, May 18th. Wall Street Zen lowered shares of Sionna Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Finally, Citizens Jmp reissued a “market outperform” rating and issued a $63.00 target price on shares of Sionna Therapeutics in a research note on Tuesday, May 26th. Three research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $53.22.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.